Clinical Trials Logo

Preeclampsia clinical trials

View clinical trials related to Preeclampsia.

Filter by:

NCT ID: NCT04075708 Completed - Preeclampsia Clinical Trials

Predicting Late-onset Preeclampsia at 10-14 Weeks of Pregnancy

Start date: August 13, 2019
Phase:
Study type: Observational

The aim of this study is to make it easier to predict late-onset preeclampsia at 11-14 weeks of pregnancy. This will be done by measuring certain proteins in the mother's blood together with obtaining the mother's medical history, ultrasound of the mother's blood supply to the uterus, and her blood pressure. All expectant mothers who meet the inclusion criteria will be invited to participate in the study, and those that agree will have the above mentioned factors measured at their first trimester scan appointment. The data will be registered in an online database, and the blood samples will be saved in a biobank at the hospital. When the women have then given birth around six months later, the data will be analyzed, and whether or not the individual woman ended up developing preeclampsia will be found out from her medical records. It will then be possible to see if blood samples, medical history, blood supply to the uterus, and/or blood pressure are connected to development of preeclampsia.

NCT ID: NCT03932877 Completed - Preeclampsia Clinical Trials

Serum Soluble Endoglin and Matrix Metalloproteinase 14 With Elisa Method in Early/Late-onset Preeclampsia

Start date: January 30, 2018
Phase:
Study type: Observational

Objective: Defective placentation and inadequate trophoblastic invasion have an important place in the aetiology of preeclampsia (PrE). Trophoblasts invade the maternal decidua and remodel spiral arteries with matrix metalloproteinase-14 (MMP-14). To the best of our knowledge, studies of MMP-14 protein levels of PrE patients' sera remain unpublished. This study aims to investigate the value of serum MMP-14 and soluble endoglin (s-ENG) in PrE patients and healthy controls. Methods: The study was conducted with 30 late-onset preeclampsia patients (L-PrE) as group1 (gestational age≥34 weeks), 33 patients with normal pregnancies as group2 (gestational age≥34 weeks), 31 early-onset preeclampsia patients (E-PrE) as group3 (gestational age<34 weeks), and 31 patients with normal pregnancies as group 4 (gestational age<34 weeks). Serum MMP-14 and s-ENG levels measured by ELISA were compared.

NCT ID: NCT03927014 Completed - Preeclampsia Clinical Trials

Thiol/Disulphide Homeostasis and Preeclampsia

thiols&PE
Start date: April 25, 2019
Phase:
Study type: Observational

Objective: To evaluate serum evaluate thiol/ disulfide levels in preeclampsia and address its relationship with its severity. Methods: This prospective study will include 50 pregnancies complicated with preeclampsia and 50 healthy pregnancies. The blood for analysis will obtain at the admission and serum thiol/ disulfide levels will measure using commercially available reagent kits. The continuous values were evaluated using Student's t-test, and categorical values were evaluated using the Chi-square test. P values < .05 were accepted as significant.

NCT ID: NCT03838965 Completed - Preeclampsia Clinical Trials

The Effects of Labor Stages and Interventions on Hemodynamic Measures During & After Childbirth With Noninvasive Sensors

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

The Effects of Labor Stages and Interventions on Hemodynamic Measures During and After Childbirth ( Epidural, Rupture Membranses Cesarean Sections and Preeclampsia) With Noninvasive Sensors.

NCT ID: NCT03801447 Completed - Preeclampsia Clinical Trials

Biomarkers and Preeclampsia Outcomes

REPORTS
Start date: April 1, 2018
Phase:
Study type: Observational

Prospective, observational, monocentric, non-interventional study.

NCT ID: NCT03749746 Completed - Obesity Clinical Trials

Heart Health 4 New Moms: A Randomized Trial in the First Year After Preeclampsia

HH4NM
Start date: January 26, 2019
Phase: N/A
Study type: Interventional

Preeclampsia causes devastating maternal and neonatal morbidity and mortality with a high recurrence risk and a rapid, occult progression to cardiovascular disease after delivery. There is a critical need for effective interventions to reduce these risks. This is a pilot randomized controlled trial of a novel postpartum lifestyle intervention compared to women who take home blood pressure measurements and women with usual care who are overweight and obese in the first year after preeclampsia. The investigators hypothesize that the intervention will lead to improved weight loss and blood pressure in the first year postpartum, which has broad implications for future pregnancy and long-term cardiovascular health.

NCT ID: NCT03567551 Completed - Preeclampsia Clinical Trials

Novel Biomarkers of Preeclampsia, Aquaporin, Fatty Acid, and S110B

Start date: May 15, 2017
Phase:
Study type: Observational

This is a research study designed to help identify preeclampsia in pregnant women earlier, and possibly lead to better treatment for women preeclampsia.

NCT ID: NCT03562715 Completed - Preeclampsia Clinical Trials

microRNAs Role in Pre-eclampsia Diagnosis

Start date: November 28, 2016
Phase:
Study type: Observational

Pre-eclampsia is one of the most threatening pregnancy complications. So far neither a secure, competent therapy for PE nor effective biomarkers for a premature discovery has been achieved.The aim of our study was to identify miRNAs 136, 494 and 495 genes expression in exosomes of peripheral blood compared to umbilical cord mesenchymal stem cells conditioned media released exososomes in patients with PE, as valuable markers for PE early prediction.

NCT ID: NCT03555630 Completed - Preeclampsia Clinical Trials

Thromboelastogram in Postdelivery Preeclamptic Patients

Start date: May 22, 2018
Phase:
Study type: Observational

There are no studies evaluating the effect of aging on hemostasis of preeclamptic patients. Additionally, although there are some studies that establish normal reference values for TEG profiles in healthy term pregnant patients, conflicting results have been found in preeclampsia. Reference values are important to establish baseline parameters in cases of pre-eclampsia complicated by postpartum hemorrhage. The investigators will evaluate reference values for TEG in postdelivery preeclamptic patients and the difference between vaginal delivery and cesarean section.

NCT ID: NCT03510286 Completed - Preeclampsia Clinical Trials

Validation of a PrCr Dipstick Diagnostic Test in Ghana

Start date: September 30, 2018
Phase:
Study type: Observational

This evaluation will aim to generate a body of evidence that will determine performance characteristics of the current PrCr dipstick test and the feasibility of its use in target ANC settings. Data will be used to inform further product development and/or support development of an introduction framework, including the process and associated resources needed for incorporation of the PrCr test into future larger-scale demonstration studies as well as to support early product launch. The objectives of the evaluation are as follows: Primary objective: Assess the accuracy of the PrCr dipstick test for detection of proteinuria in representative antenatal care settings in Ghana. Exploratory objectives: - Understand the feasibility of integrating the use of the PrCr test into ANC services in Ghana. - Explore the potential for improved ANC management of PE/E using the PrCr test in intended ANC settings versus the current standard of care used for proteinuria screening, protein-only determination via a low -cost urine dipstick test.